SVT-40776 in Patients Suffering From Overactive Bladder Syndrome

This study has been completed.

Sponsor:

Information provided by:

Salvat

ClinicalTrials.gov Identifier:

NCT00507169

First received: July 25, 2007

Last updated: June 7, 2011

Last verified: June 2011

History of Changes

Tracking Information
First Received Date ^ICMJE	July 25, 2007
Last Updated Date	June 7, 2011
Start Date ^ICMJE	September 2006
Primary Completion Date	September 2007 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE	Not Provided
Original Primary Outcome Measures ^ICMJE	Not Provided
Change History	Complete list of historical versions of study NCT00507169 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE	Not Provided
Original Secondary Outcome Measures ^ICMJE	Not Provided
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	SVT-40776 in Patients Suffering From Overactive Bladder Syndrome
Official Title ^ICMJE	Not Provided
Brief Summary	The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine
Detailed Description	Not Provided
Study Type ^ICMJE	Interventional
Study Phase	Phase 2
Study Design ^ICMJE	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment
Condition ^ICMJE	Overactive Bladder (OAB)
Intervention ^ICMJE	Drug: SVT-40776
Study Arm (s)	Not Provided
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	Not Provided
Completion Date	September 2007
Primary Completion Date	September 2007 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria: Patients suffering from OAB for at least 6 months prior to inclusion Exclusion Criteria: Pregnant and breastfeeding women Any medical condition or need for co-medication which interferes with the drug under investigation (SVT-40776) or the comparator (tolterodine)
Gender	Both
Ages	18 Years to 80 Years
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	Not Provided

Administrative Information
NCT Number ^ICMJE	NCT00507169
Other Study ID Numbers ^ICMJE	40776ORII/05IA01
Has Data Monitoring Committee	Not Provided
Responsible Party	Medical Director, Laboratorios SALVAT
Study Sponsor ^ICMJE	Salvat
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	Salvat
Verification Date	June 2011
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top